Ancora Advisors’s Pacific Biosciences PACB Stock Holding History

Ancora Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$568	Hold	430	–	–	﹤0.01%	2280
2025 Q4	$804	Hold	430	–	–	﹤0.01%	2256
2025 Q3	$550	Hold	430	–	–	﹤0.01%	1823
2025 Q2	$533	Buy	+430	New	+$497	﹤0.01%	1824
2023 Q2	–	Sell	-50	Closed	-$579	–	1881
2023 Q1	$579	Buy	+50	New	+$497	﹤0.01%	1707

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ancora Advisors's PACB Position: Q1 2026 in Review

Ancora Advisors held its Pacific Biosciences (PACB) position steady in Q1 2026 at 430 shares worth $568. The position accounts for ﹤0.01% of the portfolio, ranked #2280.

Ancora Advisors first reported a position in PACB in Q1 2023 and has held it in 5 quarters since. The position peaked at $804 in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Ancora Advisors held 430 shares of Pacific Biosciences worth $568 as of Q1 2026.
Ancora Advisors left its Pacific Biosciences share count unchanged in Q1 2026.
Pacific Biosciences made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #2280 holding.
Ancora Advisors first reported a position in Pacific Biosciences in Q1 2023 and has held it in 5 quarters since.
Ancora Advisors's Pacific Biosciences position peaked at $804 in Q4 2025.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.